Disease-modifying therapies in MS: long-term data

 

REPORT FROM AAN – BOSTON, MA, APRIL 22-28, 2017 – The following summarizes data from key studies presented at the American Academy of Neurology annual meeting on the long-term use of disease-modifying therapies in multiple sclerosis.

Teriflunomide
Dimethyl fumarate
Fingolimod
Natalizumab
Alemtuzumab
Ocrelizumab
Commentary by Daniel Selchen, MD

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page